In patients at risk, including individuals of Ashkenazi Jewish descent or those with a strong family history of pancreas cancer, the prevalence of BRCA1 and BRCA2 germline mutations has been reported in up to 19% [54,55]. This evidence concerns the gene BRCA1 and pancreatic neoplasm.